Drugs / DWJ1276
last change Jul 2013 re-read 2 minutes ago

DWJ1276

Developed for
hyperlipidemia · hypertensive disorder
Investigated by
Daewoong Pharmaceutical Co. LTD.

Trials 1 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01764295 Sep 2012 → May 2013 hyperlipidemia, hypertensive disorder Daewoong Pharmaceutical Co. LTD. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DWJ1276 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01764295
Route Oral “Once daily, administered orally, 8 week” NCT01764295